Clinical Trial: A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07700875) titled 'A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension' on July 08.

Brief Summary: The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.

Study Start Date: Dec. 29, 2022

Study Type: INTERVENTIONAL

Condition: Essential Hypertension

Intervention: DRUG: QR12000 Compound Tablets 75 mg

QR12000 Compound Tablets 75 mg QD

DRUG: QR12000 Compound Tablets 75 mg placebo

Matching placebo of QR12000 Compound Tabl...